A Trial of AXS-05 in Patients With Major Depressive Disorder (GEMINI)
AXS-05-MDD-301: A Randomized, Double-Blind, Placebo-Controlled Trial of AXS-05 in Subjects With Major Depressive Disorder
Sponsor: Axsome Therapeutics, Inc.
A PHASE3 clinical study on Depression and Major Depressive Disorder, this trial is completed. The trial is conducted by Axsome Therapeutics, Inc. and has accumulated 11 data snapshots since 2019. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Nov 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Apr 2022 — Nov 2022 [monthly]
Completed PHASE3
-
Oct 2021 — Apr 2022 [monthly]
Completed PHASE3
▶ Show 6 earlier versions
-
Apr 2021 — Oct 2021 [monthly]
Completed PHASE3
-
Jan 2021 — Apr 2021 [monthly]
Completed PHASE3
-
Feb 2020 — Jan 2021 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Nov 2019 — Feb 2020 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Sep 2019 — Nov 2019 [monthly]
Recruiting PHASE3
-
Aug 2019 — Sep 2019 [monthly]
Recruiting PHASE3
First recorded
Jun 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Axsome Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .